(redirected from Myelosuppression)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.


(computer science)
Removal or deletion usually of insignificant digits in a number, especially zero suppression.
Optional function in either on-line or off-line printing devices that permits them to ignore certain characters or groups of characters which may be transmitted through them.
Elimination of any component of an emission, as a particular frequency or group of frequencies in an audio-frequency of a radio-frequency signal.



in genetics, a phenomenon that prevents the appearance of a character resulting from mutation and that causes partial or complete restoration of the normal phenotype.

Intragenic suppression is caused by a second (suppressor) mutation in the same gene in which the first (direct) mutation occurred. Intergenic suppression is caused by a second mutation in other genes that are located at a considerable distance from the suppressed gene. In intragenic suppression, a protein coded by a given gene can reacquire functional activity, although its original structure, in contrast to true reverse mutation, or reversion, is not restored. In intergenic suppression, the normal phenotype may be restored in some cases owing to mutations that permit other means of metabolism which do not require the functioning of the given gene. In other cases, the normal phenotype may be restored as a result of mutations that alter the process by which the genetic information of the mutant gene is realized.

The phenomenon of suppression, first discovered in 1920 by the American geneticist A. H. Sturtevant, is used to study the genetic code and other aspects of molecular genetics.


Stent, G. Molekuliarnaia genetika. Moscow, 1974. Chapter 6. (Translated from English.)


References in periodicals archive ?
Kawakita et al., "Factors associated with myelosuppression related to low-dose methotrexatetherapy for inflammatory rheumatic diseases," PLoS One, vol.
Since low dose (450 mg once a day) has been shown to be equally efficacious in preventing cytomegalovirus infection when compared to high dose (900mg once a day) [160], it may be advisable to use low-dose prophylaxis to prevent myelosuppression.
In this initial phase of treatment, a dose of chemotherapy will be reduced or delayed as a result of myelosuppression and/or presence of infection, necessitating the use of other medicines to control symptoms and other complications to continue the treatment (Irving 2016; Wu and Li 2014; Caze et al 2010).
The most frequently observed adverse effects include myelosuppression, fatigue, and mucositis, and cellulitis of lower limbs has rarely been reported as an adverse event induced by pemetrexed.[sup][1] To date, the diagnosis in clinical practice is possible by excluding the other conditions that may cause ischemic colitis including inflammatory bowel disease, atrial fibrillation, valvular heart disease, and hypercoagulable conditions.
Hematopoietic stem cell transplant [HSCT] recipients have a high risk of acquiring invasive fungal infection [IFI] by virtue of prolonged myelosuppression.1 Mucormycosis is a devastating invasive fungal disease whose incidence has increased during the past decade.2,3 This mold belongs to the order Mucorales, which includes Mucor, Rhizopus, and Absidia.4-6
The herein reported case presented differential diagnostic difficulties because more likely diagnoses could be hematological malignancies, including multiple myeloma, methotrexate-induced myelosuppression, Felty's syndrome, or viral infections.
Cantharidin is potentially attractive for the treatment of leukemia because it does not cause myelosuppression [2, 3] and is effective against cells exerting the multidrug resistance phenotype [4].
Keywords: Chemotherapy, Ghrelin, Growth hormone, Leukopoiesis, Myelosuppression.
Common adverse events analyzed in the study included myelosuppression, gastrointestinal disturbance, fatigue, urinary tract infections, pathologic fracture, and progression of malignant neoplasms (1, 3).
Well-known side effects of docetaxel include peripheral neuropathy, myelosuppression, arthralgia, myalgia, fluid retention, and cutaneous reactions.
Dosage of valganciclovir had to be reduced to 450 mg BD due to persistent myelosuppression despite prophylactic injections with granulocyte colony-stimulating factor (G-CSF).
HW Alleviates Myelosuppression and Promotes Myeloid Skewing Recovery in Irradiated Mice.